Navann Ty's Stock Ratings

Exane BNP Paribas Analyst

Navann Ty is an analyst at Exane BNP Paribas. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/17/2025

Overall Average Return

26.0%

Smart Score

69.3%

Overall Average Return Percentile

86th

Number of Ratings

39
Buy NowGet Alert
08/16/2023RVNCBuy Now
Revance Therapeutics
——
Navann Ty69%
→ $20UpgradeUnderperform → NeutralGet Alert
05/30/2023KVUEBuy Now
Kenvue
$23.1421%
Navann Ty69%
→ $28Initiates → NeutralGet Alert
03/22/2022ALKSBuy Now
Alkermes
$27.20-4.41%
Navann Ty69%
$22 → $26MaintainsNeutralGet Alert
03/10/2022VTRSBuy Now
Viatris
$7.5445.79%
Navann Ty69%
$16 → $11MaintainsNeutralGet Alert
03/09/2022ENDPBuy Now
Endo International
——
Navann Ty69%
$11 → $6MaintainsBuyGet Alert
12/20/2021ZTSBuy Now
Zoetis
$148.2556.5%
Navann Ty69%
$184 → $232MaintainsNeutralGet Alert
12/01/2021ALKSBuy Now
Alkermes
$27.20-19.12%
Navann Ty69%
→ $22Initiates → NeutralGet Alert
10/05/2021JAZZBuy Now
Jazz Pharmaceuticals
$102.8794.42%
Navann Ty69%
→ $200Initiates → BuyGet Alert
08/05/2021HZNPBuy Now
Horizon Therapeutics
——
Navann Ty69%
$117 → $121MaintainsBuyGet Alert
07/23/2021OGNBuy Now
Organon
$11.01217.89%
Navann Ty69%
→ $35Initiates → BuyGet Alert
07/22/2021OGNBuy Now
Organon
$11.01217.89%
Navann Ty69%
→ $35Initiates → BuyGet Alert
06/15/2021VTRSBuy Now
Viatris
$7.54112.06%
Navann Ty69%
→ $16Initiates → NeutralGet Alert
05/12/2021ZTSBuy Now
Zoetis
$148.2524.12%
Navann Ty69%
$175 → $184MaintainsNeutralGet Alert
03/18/2021HZNPBuy Now
Horizon Therapeutics
——
Navann Ty69%
→ $120MaintainsBuyGet Alert
08/27/2020HZNPBuy Now
Horizon Therapeutics
——
Navann Ty69%
→ $112Initiates → BuyGet Alert
08/10/2020ZTSBuy Now
Zoetis
$148.257.93%
Navann Ty69%
$146 → $160MaintainsNeutralGet Alert
07/30/2020ZTSBuy Now
Zoetis
$148.25-1.51%
Navann Ty69%
$131 → $146MaintainsNeutralGet Alert
05/01/2019ALKSBuy Now
Alkermes
$27.2021.32%
Navann Ty69%
$62 → $33DowngradeBuy → NeutralGet Alert
05/01/2019HZNPBuy Now
Horizon Therapeutics
——
Navann Ty69%
$21 → $32UpgradeNeutral → BuyGet Alert
05/01/2019HZNPBuy Now
Horizon Therapeutics
——
Navann Ty69%
—UpgradeNeutral → BuyGet Alert
07/10/2018JAZZBuy Now
Jazz Pharmaceuticals
$102.8799.28%
Navann Ty69%
$162 → $205MaintainsBuyGet Alert
06/27/2018HZNPBuy Now
Horizon Therapeutics
——
Navann Ty69%
—DowngradeBuy → NeutralGet Alert
05/16/2018ALKSBuy Now
Alkermes
$27.20—
Navann Ty69%
—UpgradeNeutral → BuyGet Alert
11/28/2016HZNPBuy Now
Horizon Therapeutics
——
Navann Ty69%
—ReinstatesNeutral → BuyGet Alert
09/27/2016ALKSBuy Now
Alkermes
$27.2094.85%
Navann Ty69%
$44 → $53MaintainsNeutralGet Alert
08/09/2016HZNPBuy Now
Horizon Therapeutics
——
Navann Ty69%
$18 → $21MaintainsNeutralGet Alert
04/25/2016HZNPBuy Now
Horizon Therapeutics
——
Navann Ty69%
$21 → $18MaintainsNeutralGet Alert
01/06/2016HZNPBuy Now
Horizon Therapeutics
——
Navann Ty69%
—Assumes → NeutralGet Alert
03/27/2015ALKSBuy Now
Alkermes
$27.20161.03%
Navann Ty69%
$83 → $71DowngradeBuy → NeutralGet Alert
03/02/2015HZNPBuy Now
Horizon Therapeutics
——
Navann Ty69%
$19 → $23MaintainsBuyGet Alert
02/25/2015ALKSBuy Now
Alkermes
$27.20205.15%
Navann Ty69%
$85 → $83MaintainsBuyGet Alert
01/14/2015ALKSBuy Now
Alkermes
$27.20212.5%
Navann Ty69%
$72 → $85MaintainsBuyGet Alert
12/17/2014ALKSBuy Now
Alkermes
$27.20164.71%
Navann Ty69%
$60 → $72MaintainsBuyGet Alert
11/05/2014JAZZBuy Now
Jazz Pharmaceuticals
$102.8796.36%
Navann Ty69%
$165 → $202MaintainsBuyGet Alert
05/09/2014JAZZBuy Now
Jazz Pharmaceuticals
$102.8760.4%
Navann Ty69%
$195 → $165MaintainsBuyGet Alert
03/12/2013JAZZBuy Now
Jazz Pharmaceuticals
$102.87-27.09%
Navann Ty69%
$70 → $75MaintainsBuyGet Alert
01/15/2013ALKSBuy Now
Alkermes
$27.2010.29%
Navann Ty69%
$27 → $30MaintainsBuyGet Alert
11/27/2012JAZZBuy Now
Jazz Pharmaceuticals
$102.87-31.95%
Navann Ty69%
→ $70Initiates → BuyGet Alert
04/10/2012JAZZBuy Now
Jazz Pharmaceuticals
$102.87-41.67%
Navann Ty69%
→ $60Initiates → BuyGet Alert

Recent Analyst Stock Rating News

The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free